These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14662972)

  • 61. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995).
    Frederiksen B; Koch C; Høiby N
    Pediatr Pulmonol; 1999 Sep; 28(3):159-66. PubMed ID: 10495331
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Host inflammatory responses to first isolation of Pseudomonas aeruginosa from sputum in cystic fibrosis.
    Elborn JS; Cordon SM; Shale DJ
    Pediatr Pulmonol; 1993 May; 15(5):287-91. PubMed ID: 8327287
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular epidemiological analysis suggests cross-infection with Pseudomonas aeruginosa is rare in non-cystic fibrosis bronchiectasis.
    De Soyza A; Perry A; Hall AJ; Sunny SS; Walton KE; Mustafa N; Turton J; Kenna DT; Winstanley C
    Eur Respir J; 2014 Mar; 43(3):900-3. PubMed ID: 24176999
    [No Abstract]   [Full Text] [Related]  

  • 64. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
    Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adhesins and receptors of Pseudomonas aeruginosa associated with infection of the respiratory tract.
    Prince A
    Microb Pathog; 1992 Oct; 13(4):251-60. PubMed ID: 1363702
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence.
    Bragonzi A; Paroni M; Nonis A; Cramer N; Montanari S; Rejman J; Di Serio C; Döring G; Tümmler B
    Am J Respir Crit Care Med; 2009 Jul; 180(2):138-45. PubMed ID: 19423715
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis.
    Douglas TA; Brennan S; Berry L; Winfield K; Wainwright CE; Grimwood K; Stick SM; Sly PD;
    Thorax; 2010 Nov; 65(11):985-90. PubMed ID: 20889526
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prevention of severe lower respiratory infections in patients with cystic fibrosis.
    Speert DP
    Semin Respir Infect; 1989 Dec; 4(4):266-71. PubMed ID: 2516638
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The pathogenesis of Pseudomonas aeruginosa lung infections in cystic fibrosis.
    Grimwood K
    J Paediatr Child Health; 1992 Feb; 28(1):4-11. PubMed ID: 1554515
    [No Abstract]   [Full Text] [Related]  

  • 70. Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis.
    Stotland PK; Radzioch D; Stevenson MM
    Pediatr Pulmonol; 2000 Nov; 30(5):413-24. PubMed ID: 11064433
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.
    Burns JL; Gibson RL; McNamara S; Yim D; Emerson J; Rosenfeld M; Hiatt P; McCoy K; Castile R; Smith AL; Ramsey BW
    J Infect Dis; 2001 Feb; 183(3):444-52. PubMed ID: 11133376
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Upper aero-digestive contamination by Pseudomonas aeruginosa and implications in Cystic Fibrosis.
    Rivas Caldas R; Boisramé S
    J Cyst Fibros; 2015 Jan; 14(1):6-15. PubMed ID: 24933711
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
    Wiesemann HG; Steinkamp G; Ratjen F; Bauernfeind A; Przyklenk B; Döring G; von der Hardt H
    Pediatr Pulmonol; 1998 Feb; 25(2):88-92. PubMed ID: 9516091
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Infection prevention and control in patients with cystic fibrosis (CF): Results from a survey in 35 German CF treatment centers.
    Meyer S; Nüßlein T; Nährlich L; Bend J; Gärtner B; Becker SL; Simon A
    J Cyst Fibros; 2020 May; 19(3):384-387. PubMed ID: 31680044
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Microbial ecology and adaptation in cystic fibrosis airways.
    Yang L; Jelsbak L; Molin S
    Environ Microbiol; 2011 Jul; 13(7):1682-9. PubMed ID: 21429065
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
    Taccetti G; Campana S; Festini F; Mascherini M; Döring G
    Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mucoid Pseudomonas aeruginosa from a patient without cystic fibrosis: implications and review of the literature.
    McCarthy VP; Rosenberg G; Rosenstein BJ; Hubbard VS
    Pediatr Infect Dis; 1986; 5(2):256-8. PubMed ID: 3081882
    [No Abstract]   [Full Text] [Related]  

  • 78. Bacterial precipitins in serum of patients with cystic fibrosis.
    Burns MW; May JR
    Lancet; 1968 Feb; 1(7537):270-2. PubMed ID: 4170754
    [No Abstract]   [Full Text] [Related]  

  • 79. Failure of local defense mechanisms in cystic fibrosis.
    Proesmans M; De Boeck K
    Acta Otorhinolaryngol Belg; 2000; 54(3):367-72. PubMed ID: 11082773
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chronic Pseudomonas aeruginosa infection and respiratory muscle impairment in cystic fibrosis.
    Dassios TG; Katelari A; Doudounakis S; Dimitriou G
    Respir Care; 2014 Mar; 59(3):363-70. PubMed ID: 23983273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.